ESC 365 - Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials.

ESC Premium Access

Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials.

Session: Poster Session 6 - Lipids

Topic: Drug therapy

Speaker: Doctor H. Siddiqi (Boston, US)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Hasan Siddiqi

Brigham and Women's Hospital, Boston (United States of America)

1 presentation

0 follower

13 more presentations in this session

Reduction in high-sensitivity C-reactive protein by pitavastatin was associated with improved outcomes in Japanese patients with stable coronary artery disease: results from REAL-CAD study

Speaker: Doctor H. Iwata (Tokyo, JP)

The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry

Speaker: Professor E. Liberopoulos (Athens, GR)

Oxidized phospholipids on apolipoprotein B-100 among black US adults with and without PCSK9 loss-of-function variants

Speaker: Doctor M. Mefford (Birmingham, US)

HDL-C and all-cause mortality in a high-risk population: impact of LDL-C

Speaker: Doctor D. Dhindsa (Atlanta, US)

Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry

Speaker: Professor E. Liberopoulos (Athens, GR)

Access the full session

Poster Session 6 - Lipids

Speakers: Doctor H. Siddiqi, Doctor H. Iwata, Professor E. Liberopoulos, Doctor M. Mefford, Doctor D. Dhindsa...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources